Please use this identifier to cite or link to this item: https://www.um.edu.mt/library/oar/handle/123456789/149941
Title: Sepsis in patients who are immunocompromised : diagnostic challenges and future therapies
Authors: Deinhardt-Emmer, Stefanie
Chousterman, Benjamin G.
Schefold, Joerg C.
Flohé, Stefanie B.
Skirecki, Tomasz
Kox, Matthijs
Winkler, Martin S.
Cossarizza, Andrea
Joost Wiersinga, W.
van der Poll, Tom
Weigand, Markus A.
Cajander, Sara
Giamarellos-Bourboulis, Evangelos
Lachmann, Gunnar
Girardis, Massimo
Scicluna, Brendon P.
Ferrer, Ricard
Payen, Didier
Weis, Sebastian
Torres, Antoni
Bermejo-Martín, Jesús F.
Osuchowski, Marcin F.
Rubio, Ignacio
Bouma, Hjalmar R.
Keywords: Septicemia
Immunocompromised host
Immunosuppressive agents
Immunological deficiency syndromes -- Complications
Issue Date: 2025
Publisher: The Lancet Publishing Group
Citation: Deinhardt-Emmer, S., Chousterman, B. G., Schefold, J. C., Flohé, S. B., Skirecki, T., Kox, M.,...Bouma, H. R. (2025). Sepsis in patients who are immunocompromised: diagnostic challenges and future therapies. The Lancet Respiratory Medicine, 13(7), 623-637.
Abstract: Sepsis is a life-threatening, dysregulated host response to infection. Immunosuppression is a risk factor for infections and sepsis. However, the specific immune derangements elevating the risk for infections and sepsis remain unclear in the individual patient, raising the question of whether a general state of immunosuppression exists. In this Review, we explore the relationship between immunosuppression and sepsis, detailing the definitions, causes, and clinical implications. We address the effect of primary immunodeficiencies, acquired conditions, and drugs on the risk of infection and the development of sepsis. Patients with sepsis who are immunocompromised often present with atypical symptoms and diagnostic test results can differ, making early recognition difficult. Future perspectives entail novel biomarkers to improve early sepsis detection and tailored treatments to modulate immune function. Including patients who are immunocompromised in clinical trials is crucial to enhance the relevance of research findings and improve treatment strategies for this vulnerable population.
URI: https://www.um.edu.mt/library/oar/handle/123456789/149941
Appears in Collections:Scholarly Works - FacHScABS

Files in This Item:
File Description SizeFormat 
Sepsis_in_patients_who_are_immunocompromised.pdf2.02 MBAdobe PDFView/Open


Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.